Clinical trials
Sexually Transmitted Infections (Not HIV or Hepatitis) clinical trials
Below are recruiting sexually transmitted infections (not hiv or hepatitis) clinical trials, each written for real people, not researchers. We’re tracking 778 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06718530Recruiting
Finding early markers for liver cancer in people with chronic liver disease
This study looks for substances in your blood and immune system that could help doctors find liver cancer earlier. It is for people with liver cancer caused by chronic liver problems like hepatitis C, cirrhosis, or scarring.
Aviano, PordenoneAges 18 years+ - NCT07589985Recruiting
Hepatitis B and Liver Health Study in Zambia
This research study follows people with hepatitis B (a liver infection) in Zambia to understand how their bodies respond to treatment and what happens to the virus over time. It includes people with hepatitis B alone, those also living with HIV, and those whose hepatitis B has cleared.
LusakaAges 18 years+ - NCT07542951Enrolling by invitationPhase 4
TAF vs TDF antiviral treatment during pregnancy for hepatitis B
This study compares two antiviral medications (TAF and TDF) in pregnant women with hepatitis B to see which is safer and more effective during pregnancy and for the baby's health.
Guangzhou, GuangdongAges 20–40 - NCT06746701Recruiting
Peginterferon with NA to prevent liver cancer in hepatitis B
This study tests whether combining peginterferon alpha-2b with a nucleoside analog can lower liver cancer risk in people with chronic hepatitis B who have a family history of liver cancer. It compares the combination therapy to nucleoside analog alone.
Guangzhou, GuangdongAges 18–65 - NCT07525544RecruitingPhase 1
Safety Study of VH4770359 in Healthy Adults
This is an early-stage safety study testing a new investigational drug (VH4770359) in healthy volunteers. Researchers want to understand how the body processes the drug and ensure it is safe and well-tolerated.
Baltimore, MarylandAges 18–55 - NCT07530198RecruitingPhase 1
HIV DNA vaccine test for people on stable treatment
This study tests a new DNA vaccine (ICVAX) designed to help your immune system better control HIV. You'll receive injections over several months if your HIV is well-controlled with current medications.
Shatin, New TerritoriesAges 18–60 - NCT07442760Recruiting
Diary study for hepatitis D virus patients
This study uses a mobile diary app to track symptoms and quality of life for people living with hepatitis D infection. It may help researchers better understand the patient experience.
Bergamo, ItalyAges 18 years+ - NCT07357584RecruitingPhase 4
Quick-start HIV treatment with doravirine for newly diagnosed adults
This study tests a fast-start HIV treatment using doravirine, tenofovir, and lamivudine for people who were just diagnosed with HIV in the last 30 days and have never taken HIV medications before. The goal is to see if starting treatment right away is safe and effective.
Ciudad Autonoma de Buenos Aire, Buenos AiresAges 18–90 - NCT07308782RecruitingPhase 2
Testing a new HIV treatment in people not yet on therapy
This trial is testing an experimental HIV pill called CL-197. It's for people with HIV who have never taken any HIV medicines before. The study lasts about 2 weeks and aims to see how the drug works in the body.
BeijingAges 18–60 - NCT06874127Recruiting
Predicting liver repair in hepatitis B after treatment
This study looks at whether non-invasive tests can tell if liver damage is reversing in people with hepatitis B who have been on antiviral therapy for at least a year. It aims to help avoid repeated liver biopsies.
BeijingAges 18 years+ - NCT06889805Recruiting
HDV screening for HIV and hepatitis B patients
This study tests whether people with both HIV and chronic hepatitis B should be checked for a third liver virus called HDV (hepatitis D). It helps find hidden infections so they can get the right care.
Hong KongAges 18 years+ - NCT07199998Recruiting
How tampons and cups affect your vaginal health
This study looks at how tampons and menstrual cups affect your body's natural defenses and the healthy bacteria in your vagina. You might join if you are a healthy woman between 18 and 49 who has regular periods and uses or is willing to use these products.
Paris, Île-de-France RegionAges 18–49 - NCT07179575RecruitingPhase 1/Phase 2
Study of LW231 for people with chronic hepatitis B
This trial tests a new drug, LW231, in people with chronic hepatitis B. It aims to see if the drug can reduce the amount of virus and surface antigen in your blood, and if it is safe for you.
Hangzhou, ZhejiangAges 18–60 - NCT07122219Recruiting
Needle exchange access in federal prisons
This study looks at whether making needle and syringe programs easier to use helps more people in prison get clean needles. It's about reducing infection risks for everyone at the participating prisons.
Edmonton, AlbertaAges 18 years+ - NCT05936073Recruiting
Study of patient data for people with HDV infection
This study looks at patient information (your health data) for adults who test positive for HDV. You may help researchers better understand HDV by allowing their team to collect and use your data.
LimogesAges 18 years+ - NCT07031063RecruitingPhase 4
HIV treatment study for people starting therapy
This study compares two HIV medications (DTG/3TC and BIC/TAF/FTC) to see which works better and is safer for people who have never taken HIV treatment before. It may help you find a once-daily pill that controls the virus and has fewer side effects.
Mexico City, AzcapotzalcoAges 18 years+ - NCT06774872RecruitingPhase 2
Comparing two-drug HIV maintenance treatments
This trial compares a two-drug regimen of doravirine and lamivudine to another two-drug regimen of dolutegravir and lamivudine for people with HIV who have had a suppressed viral load for at least 24 months. The goal is to see if the newer combination works as well as the current one.
Paris, Île-de-France RegionAges 18 years+ - NCT06665646RecruitingPhase 1
HIV vaccine booster study for previous trial participants
This study tests a booster vaccine for HIV in people who were part of an earlier HIV vaccine trial. The goal is to see if it's safe and helps the immune system fight HIV better.
San Francisco, CaliforniaAges 18–60 - NCT05853718RecruitingPhase 4
Tenofovir treatment for hepatitis B during pregnancy
This study tests tenofovir alafenamide (TAF) to lower hepatitis B in pregnant people and reduce the chance of passing it to the baby. You may be able to join if you’re pregnant with active hepatitis B and meet safety lab and pregnancy ultrasound requirements.
Hangzhou, ZhejiangAges 20–40 - NCT06504485Recruiting
Study of bulevirtide for chronic hepatitis B and D
This trial tests a drug called bulevirtide for people with chronic hepatitis B and D (HDV) co-infection. It looks at how the immune system and virus respond to treatment.
MilanAges 18 years+ - NCT06310551RecruitingPhase 1
Long-acting HIV prevention study for healthy adults
This study tests a new long-acting medicine that may help prevent HIV. It is given as an injection, and the study checks how safe it is and how it works in healthy volunteers.
Lenexa, KansasAges 18–55 - NCT06047093Recruiting
Study of Hepatitis B Virus in the Liver
This study collects a small sample of liver cells to understand how hepatitis B virus behaves in the liver and how the immune system responds. This could help improve future treatments for chronic hepatitis B.
LyonAges 18 years+ - NCT05653232Recruiting
Preventing hepatitis C in kidney transplant recipients using antiviral pills
This study tests antiviral medicine given around the time of a kidney transplant to prevent hepatitis C infection when the donor has hepatitis C. It may help uninfected recipients stay hepatitis C–free after receiving the kidney.
La Jolla, CaliforniaAges 18 years+ - NCT05418868RecruitingPhase 1
Long-acting cabotegravir injection safety in healthy adults
This Phase 1 study tests how the body handles a long-acting (slow-release) cabotegravir injection combined with a drug called hyaluronidase. It also checks safety and side effects in healthy adults to help future HIV-prevention or treatment plans.
Orlando, FloridaAges 18–55
Hear when a new Sexually Transmitted Infections (Not HIV or Hepatitis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for sexually transmitted infections (not hiv or hepatitis)?
- Yes. Clin2 currently lists 778 recruiting sexually transmitted infections (not hiv or hepatitis) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a sexually transmitted infections (not hiv or hepatitis) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a sexually transmitted infections (not hiv or hepatitis) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.